{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:43:07Z","timestamp":1787236987365,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,25]],"date-time":"2017-11-25T00:00:00Z","timestamp":1511568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Evidence-based Healthcare Collaborating Agency (KR)","award":["NA2015-001"],"award-info":[{"award-number":["NA2015-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10096-017-3133-2","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T18:31:44Z","timestamp":1511548304000},"page":"305-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study"],"prefix":"10.1007","volume":"37","author":[{"given":"J.-H.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-J.","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-y.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,25]]},"reference":[{"key":"3133_CR1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA (2007) Comparative review of the carbapenems. Drugs 67:1027\u20131052","journal-title":"Drugs"},{"key":"3133_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-200363040-00002","volume":"63","author":"ME Rupp","year":"2003","unstructured":"Rupp ME, Fey PD (2003) Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63:353\u2013365","journal-title":"Drugs"},{"issue":"Suppl 1","key":"3133_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1469-0691.2007.01850.x","volume":"14","author":"R Canton","year":"2008","unstructured":"Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM (2008) Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14(Suppl 1):144\u2013153. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2007.01850.x","journal-title":"Clin Microbiol Infect"},{"key":"3133_CR4","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1128\/aac.00971-12","volume":"57","author":"WH Sheng","year":"2013","unstructured":"Sheng WH, Badal RE, Hsueh PR (2013) Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother 57:2981\u20132988. \nhttps:\/\/doi.org\/10.1128\/aac.00971-12","journal-title":"Antimicrob Agents Chemother"},{"key":"3133_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/jac\/dki166","volume":"56","author":"JD Pitout","year":"2005","unstructured":"Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52\u201359. \nhttps:\/\/doi.org\/10.1093\/jac\/dki166","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"3133_CR6","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1086\/430789","volume":"41","author":"PJ Turner","year":"2005","unstructured":"Turner PJ (2005) Extended-spectrum beta-lactamases. Clin Infect Dis 41(Suppl 4):S273\u2013S275. \nhttps:\/\/doi.org\/10.1086\/430789","journal-title":"Clin Infect Dis"},{"key":"3133_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3201\/eid1710.110655","volume":"17","author":"P Nordmann","year":"2011","unstructured":"Nordmann P, Naas T, Poirel L (2011) Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791\u20131798. \nhttps:\/\/doi.org\/10.3201\/eid1710.110655","journal-title":"Emerg Infect Dis"},{"key":"3133_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","volume":"75","author":"D Duin van","year":"2013","unstructured":"van Duin D, Kaye KS, Neuner EA, Bonomo RA (2013) Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75:115\u2013120. \nhttps:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.11.009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3133_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3947\/ic.2014.46.3.149","volume":"46","author":"CS Lee","year":"2014","unstructured":"Lee CS, Doi Y (2014) Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 46:149\u2013164. \nhttps:\/\/doi.org\/10.3947\/ic.2014.46.3.149","journal-title":"Infect Chemother"},{"key":"3133_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jhin.2009.02.021","volume":"73","author":"ME Falagas","year":"2009","unstructured":"Falagas ME, Karageorgopoulos DE (2009) Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 73:345\u2013354. \nhttps:\/\/doi.org\/10.1016\/j.jhin.2009.02.021","journal-title":"J Hosp Infect"},{"key":"3133_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/cid\/cir202","volume":"53","author":"N Gupta","year":"2011","unstructured":"Gupta N, Limbago BM, Patel JB, Kallen AJ (2011) Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53:60\u201367. \nhttps:\/\/doi.org\/10.1093\/cid\/cir202","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"3133_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1469-0691.2007.01864.x","volume":"14","author":"LR Peterson","year":"2008","unstructured":"Peterson LR (2008) Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 14(Suppl 1):181\u2013184. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2007.01864.x","journal-title":"Clin Microbiol Infect"},{"key":"3133_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/420816","volume":"39","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL (2004) Antibiotic therapy for Klebsiella Pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39:31\u201337. \nhttps:\/\/doi.org\/10.1086\/420816","journal-title":"Clin Infect Dis"},{"key":"3133_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1756-0500-3-116","volume":"3","author":"VP Chaubey","year":"2010","unstructured":"Chaubey VP, Pitout JD, Dalton B, Ross T, Church DL, Gregson DB, Laupland KB (2010) Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes 3:116. \nhttps:\/\/doi.org\/10.1186\/1756-0500-3-116","journal-title":"BMC Res Notes"},{"key":"3133_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1017\/ice.2015.101","volume":"36","author":"H Ofer-Friedman","year":"2015","unstructured":"Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D (2015) Carbapenems versus piperacillin-Tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum Beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 36:981\u2013985. \nhttps:\/\/doi.org\/10.1017\/ice.2015.101","journal-title":"Infect Control Hosp Epidemiol"},{"key":"3133_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","volume":"80","author":"HY Tsai","year":"2014","unstructured":"Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR (2014) Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis 80:222\u2013226. \nhttps:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.07.006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3133_CR17","doi-asserted-by":"publisher","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","volume":"11","author":"TM Ng","year":"2016","unstructured":"Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC (2016) Empiric piperacillin-Tazobactam versus carbapenems in the treatment of Bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS One 11:e0153696. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0153696","journal-title":"PLoS One"},{"key":"3133_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","volume":"64","author":"CI Kang","year":"2012","unstructured":"Kang CI, Park SY, Chung DR, Peck KR, Song JH (2012) Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia Coli and Klebsiella Pneumoniae. J Inf Secur 64:533\u2013534. \nhttps:\/\/doi.org\/10.1016\/j.jinf.2012.01.008","journal-title":"J Inf Secur"},{"key":"3133_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"J Rodriguez-Bano","year":"2012","unstructured":"Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A (2012) Beta-lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia Coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167\u2013174. \nhttps:\/\/doi.org\/10.1093\/cid\/cir790","journal-title":"Clin Infect Dis"},{"key":"3133_CR20","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/j.ijid.2012.09.008","volume":"17","author":"KK To","year":"2013","unstructured":"To KK, Lo WU, Chan JF, Tse H, Cheng VC, Ho PL (2013) Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. Int J Infect Dis 17:e120\u2013e124. \nhttps:\/\/doi.org\/10.1016\/j.ijid.2012.09.008","journal-title":"Int J Infect Dis"},{"key":"3133_CR21","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1128\/aac.48.12.4574-4581.2004","volume":"48","author":"CI Kang","year":"2004","unstructured":"Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004) Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574\u20134581. \nhttps:\/\/doi.org\/10.1128\/aac.48.12.4574-4581.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"3133_CR22","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/jac\/dks301","volume":"67","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67:2793\u20132803. \nhttps:\/\/doi.org\/10.1093\/jac\/dks301","journal-title":"J Antimicrob Chemother"},{"key":"3133_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"3133_CR24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818\u2013829","journal-title":"Crit Care Med"},{"key":"3133_CR25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791\u2013797","journal-title":"Ann Intern Med"},{"key":"3133_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1128\/cmr.00116-14","volume":"28","author":"AJ Mathers","year":"2015","unstructured":"Mathers AJ, Peirano G, Pitout JD (2015) The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev 28:565\u2013591. \nhttps:\/\/doi.org\/10.1128\/cmr.00116-14","journal-title":"Clin Microbiol Rev"},{"key":"3133_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3947\/ic.2013.45.1.51","volume":"45","author":"JC Kwon","year":"2013","unstructured":"Kwon JC, Kim SH, Choi JK, Cho SY, Park YJ, Park SH, Choi SM, Lee DG, Choi JH, Yoo JH (2013) Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center. Infect Chemother 45:51\u201361. \nhttps:\/\/doi.org\/10.3947\/ic.2013.45.1.51","journal-title":"Infect Chemother"},{"key":"3133_CR28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/jac\/dkv441","volume":"71","author":"EA Reuland","year":"2016","unstructured":"Reuland EA, Al Naiemi N, Kaiser AM, Heck M, Kluytmans JA, Savelkoul PH, Elders PJ, Vandenbroucke-Grauls CM (2016) Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother 71:1076\u20131082. \nhttps:\/\/doi.org\/10.1093\/jac\/dkv441","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"3133_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1469-0691.2007.01855.x","volume":"14","author":"PM Hawkey","year":"2008","unstructured":"Hawkey PM (2008) Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 14(Suppl 1):159\u2013165. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2007.01855.x","journal-title":"Clin Microbiol Infect"},{"key":"3133_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/00365548.2013.775479","volume":"45","author":"CI Kang","year":"2013","unstructured":"Kang CI, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, Song JH (2013) Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia Coli, with a special emphasis on antimicrobial therapy. Scand J Infect Dis 45:519\u2013525. \nhttps:\/\/doi.org\/10.3109\/00365548.2013.775479","journal-title":"Scand J Infect Dis"},{"key":"3133_CR31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/jac\/dks065","volume":"67","author":"WC Rottier","year":"2012","unstructured":"Rottier WC, Ammerlaan HS, Bonten MJ (2012) Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67:1311\u20131320. \nhttps:\/\/doi.org\/10.1093\/jac\/dks065","journal-title":"J Antimicrob Chemother"},{"key":"3133_CR32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1469-0691.2011.03658.x","volume":"18","author":"ZA Qureshi","year":"2012","unstructured":"Qureshi ZA, Paterson DL, Peleg AY, Adams-Haduch JM, Shutt KA, Pakstis DL, Sordillo E, Polsky B, Sandkovsky G, Bhussar MK, Doi Y (2012) Clinical characteristics of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type beta-lactamases. Clin Microbiol Infect 18:887\u2013893. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2011.03658.x","journal-title":"Clin Microbiol Infect"},{"key":"3133_CR33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/cid\/civ003","volume":"60","author":"PD Tamma","year":"2015","unstructured":"Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE (2015) Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis 60:1319\u20131325. \nhttps:\/\/doi.org\/10.1093\/cid\/civ003","journal-title":"Clin Infect Dis"},{"key":"3133_CR34","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1093\/jac\/dkv153","volume":"70","author":"JM Costa Ramos","year":"2015","unstructured":"Costa Ramos JM, Stein C, Pfeifer Y, Brandt C, Pletz MW, Makarewicz O (2015) Mutagenesis of the CTX-M-type ESBL-is MIC-guided treatment according to the new EUCAST recommendations a safe approach? J Antimicrob Chemother 70:2528\u20132535. \nhttps:\/\/doi.org\/10.1093\/jac\/dkv153","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-017-3133-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-3133-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-3133-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T19:54:07Z","timestamp":1516737247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-017-3133-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,25]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3133"],"URL":"https:\/\/doi.org\/10.1007\/s10096-017-3133-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732181839.793549913","asserted-by":"object"}]},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,25]]}}}